<DOC>
	<DOCNO>NCT00751153</DOCNO>
	<brief_summary>Subjects HIV viral suppression current regimen also side effects/intolerance change current regimen combination Raltegravir Atazanavir monitor viral immunological response quality life .</brief_summary>
	<brief_title>Raltegravir Atazanavir Replacing Current Suppressive Treatment Because Side Effects Current Treatment</brief_title>
	<detailed_description>Subjects intolerance current regimen receive Raltegravir 400 mg twice daily Atazanavir 400 mg daily monitor viralogical immunological outcome , change lipid , renal hepatic safety quality life .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Inclusion Criteria History PI resistance antiretroviral failure receive PI . On current antiviral regimen plasma HIV viral load ( VL ) &lt; 400 copies/ml 4 month longer . Intolerance toxicity current alternative regimen ( ) side effect include limited gastrointestinal , neurological , metabolic , dysmorphic symptom and/or dyslipidemia . Continuously use regimen 3 month prior Screening . Women childbearing potential must willing use effective method ( ) contraception throughout study participation 30 day follow end study ( see Section 1.10 ) . Women postmenopausal least 2 year , woman total hysterectomy woman tubal ligation consider nonchildbearing potential . Willing adhere prohibition restriction specify protocol . Use drug contraindicate current US package insert Atazanavir investigator brochure Raltegravir , include PPI inhibitor . Use investigational drug 4 week prior screen . Prior current therapy Raltegravir . Allergy Raltegravir Atazanavir History medication noncompliance significant study regimen deem significant investigator . Known achlorhydria would inhibit absorption Atazanavir Concurrent active chronic Hepatitis B require therapy 3TC , FTC Tenofovir ( entecavir permit ) . AST ALT &gt; 5 time ULN Calculated CrCl &lt; 30 ml/min . Female subject pregnant breastfeeding . General medical condition may interfere assessment completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>drug substitution</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>treatment Experienced</keyword>
</DOC>